Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

Trial Profile

Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 29 May 2018

At a glance

  • Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Nivolumab (Primary) ; Pomalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 22 May 2018 Status changed from recruiting to discontinued due to safety reasons.
    • 09 Sep 2017 Status changed from not yet recruiting to recruiting.
    • 20 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top